IngredientesAlgal oil is a lipid extract derived from microalgae that is particularly rich in long-chain omega-3 polyunsaturated fatty acids (LC-PUFAs), principally docosahexaenoic acid (DHA) and, depending on the species, eicosapentaenoic acid (EPA). Several different omega-3s exist, but the majority of scientific research focuses on three: alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). ALA contains 18 carbon atoms, whereas EPA and DHA are considered long-chain omega-3s because EPA contains 20 carbons and DHA contains 22. DHA is an omega-3 fatty acid — a type of polyunsaturated fatty acid (PUFA) with 6 carbon double bonds — with the basic molecular formula C₂₂H₃₂O₂.
DHA and EPA are present in fish, fish oils, and krill oils, but they are originally synthesized by microalgae at the base of the marine food chain, not by the fish. As microalgae move up the food chain, fish acquire the omega-3s and accumulate them in their tissues. Algal oil production therefore captures omega-3s directly at their biosynthetic origin.
Algal oil is an oil from marine algae that is rich in certain omega-3 fatty acids, including docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Certain algae species are grown in agriculture specifically to produce algal oil. It can be made from a variety of species, including Crypthecodinium, Nannochloropsis, Schizochytrium, Prototheca, and Ulkenia.
The most commonly used microalgae for the production of omega-3-rich algal oil and biomass are marine members of the families Thraustochytriaceae and Crypthecodiniaceae, which are present in the oceans. Crypthecodinium is a genus of the family Crypthecodiniaceae. The Thraustochytrids include the genera Aurantiochytrium, Schizochytrium, and Ulkenia. These heterotrophs can display a high oil content (up to 50–77% on a dry weight basis) which is mainly composed of triacylglycerols (TAGs) rich in DHA.
Schizochytrium sp., a heterotrophic marine microalga, has become a revolutionary and sustainable source of omega-3 fatty acids, particularly DHA, which constitutes 35–50% of its lipids. Identified in the 1960s, its significance lies in offering a scalable and environmentally friendly alternative to fish oil, addressing overfishing with a lower carbon footprint.
Martek Biosciences (acquired by Royal DSM NV in 2011) developed commercial edible DHA from both main algal sources. One of Martek's proprietary products was demonstrated to have similar nutritional properties to cooked salmon. The company's DHASCO product, derived from C. cohnii, has a DHA content of over 40% and its safety and bioaccessibility has enabled its use in infant formula, baby foods, dietary supplements, and pharmaceuticals.
The specific fatty acid profile of algal oil varies by genus and production strain. Algal oil derived from Schizochytrium sp. contains not less than 35% DHA, and additionally contains approximately 16.1% (22:5 ω6) docosapentaenoic acid, 1.3% (20:5 ω3) eicosapentaenoic acid, 0.6% (20:4 ω6) arachidonic acid, 1.6% (18:2 ω6) linoleic acid, and 16.9% (18:1 ω9) oleic acid. Oils produced from algae typically contain more DHA than fish oil (20–55% of fatty acids) with some EPA. Algal oil also contains other important fatty acids called omega-9 fatty acids.
Algal oil is typically found in capsule form, but can also be found as a liquid. It can be taken by the spoonful or used in cooking. The petitioned use of DHA algal oil is as an ingredient and as a source of DHA in foods, beverages, infant formulas, and as a dietary supplement. Consistency of composition, sensory properties such as aroma, taste, texture, and appearance, ease of production, lack of contaminants, and low cholesterol are the key features of omega-3 fatty acid production using algal oil. Algal oils are odorless, scalable, vegan, and easier to cultivate.
Unlike many botanical supplements with ancient use histories, algal oil as an isolated nutritional ingredient is an entirely modern development, with no documented pre-industrial or traditional medicinal use in any culture. Its history is one of 20th-century scientific discovery and commercial biotechnology rather than ethnobotany.
Early production of algal-sourced long-chain PUFAs (LC-PUFAs) involved predominantly DHA. The principal species used were from either fermentation of Schizochytrium sp. or the heterotrophic Crypthecodinium cohnii. Before the large-scale production of DHA algal oil for fatty acid supplementation of infant formula, fish oil was the primary source of fatty acids for formula-fed infants.
The FDA responded without objection to a GRAS (Generally Recognized as Safe) notification on algal oil DHA from Martek Biosciences Corporation. Martek estimated that the use of algal oil in a number of food categories at the maximum proposed use levels would result in a mean exposure of no more than 1.5 grams of DHA per day (GRAS Notice No. GRN000137). This regulatory milestone marked the entry of algal oil as a mainstream food ingredient in the United States, particularly in infant formula.
The underlying rationale for algal oil supplementation was the recognition that sustainability concerns regarding global fish stocks, together with ever-growing demand from the aquaculture industry, were key factors in driving the demand for alternative sources of the long-chain PUFAs EPA and DHA. Microalgae are the prime source of LC-PUFAs for fish and other organisms.
The primary bioactive constituents of algal oil are the long-chain omega-3 polyunsaturated fatty acids DHA (C22:6n-3) and EPA (C20:5n-3). Omega-3s are important components of the membranes that surround each cell in the body. DHA levels are especially high in retina (eye), brain, and sperm cells. Omega-3s also provide calories and have many functions in the heart, blood vessels, lungs, immune system, and endocrine system.
DHA (22:6 omega-3) is a long-chain polyunsaturated fatty acid belonging to the ω-3 family. DHA possesses a 22-carbon chain and 6 cis double bonds (22:6n-3) and is highly concentrated in neural tissues. During cerebral development, it has been observed to accumulate in the fetal brain. Some studies have shown that reduced levels of DHA in the brain have been associated with impaired neurogenesis and neurite growth and altered metabolism of several neurotransmitters, including dopamine, serotonin, and acetylcholine.
The human conversion of ALA to EPA and DHA is inherently limited due to Δ6-desaturase and elongase enzyme constraints, with efficiency affected by genetic, hormonal, and dietary factors. Therefore, consuming EPA and DHA directly from foods and/or dietary supplements is the only practical way to increase levels of these fatty acids in the body.
The cardioprotective effect of EPA and DHA is most likely due to the beneficial modulation of a number of known risk factors for CVD, such as blood lipids, blood pressure, heart rate and heart rate variability, platelet aggregation, endothelial function, and inflammation. N-3 PUFAs combine their indirect effects on metabolic, inflammatory and thrombogenic parameters with direct effects at the cellular level. The anti-fibrotic effects of n-3 PUFA have been described, with potential impacts on heart failure with a preserved ejection fraction. Furthermore, n-3 PUFAs can modify ion channels, with a favorable impact on arrhythmias.
Among nutritional strategies to prevent and/or reduce chronic inflammation, long-chain omega-3 PUFAs (LCn-3PUFA), notably EPA and DHA, have raised considerable interest for their purported anti-inflammatory effects. Previous meta-analyses of randomized controlled trials substantiated the anti-inflammatory effect of LCn-3PUFA supplementation, as evidenced by significant reductions in plasma concentrations of specific inflammation markers such as C-reactive protein (CRP) and tumor necrosis factor alpha (TNF-alpha).
Previous studies have shown that antibiotic-induced disturbances of the intestinal barrier and intestinal microbiota can be modulated by supplementation with n-3 PUFA polyunsaturated fatty acids such as algal oil and fish oil. At the molecular level, supplementation with algal oil upregulated the concentration of tight junction protein ZO-1, which is important for maintaining intestinal barrier integrity.
Evidence strength: Moderate to strong for triglyceride reduction; well-supported by multiple RCTs and meta-analyses.
The cardiovascular benefits of fish-derived long-chain polyunsaturated fatty acids — DHA and EPA — are well established. Less studied are the specific effects of individual long-chain PUFAs. Based on data from 16 published clinical trials, one review examined effects of DHA triglyceride oil derived from algae (algal-DHA) on serum triglyceride levels and related parameters.
At doses of 1–2 g/d, algal-DHA significantly lowered plasma triglyceride levels (up to 26%) either administered alone or in combination with statins. The reduction in triglyceride levels was markedly greater in hypertriglyceridemic than in normal subjects. Algal-DHA modestly increased plasma levels of both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol. The increased plasma level of LDL cholesterol was associated with a shift of lipoprotein particle size toward larger, less atherogenic subfractions.
A 2012 meta-analysis provided further systematic evidence. Researchers conducted a systematic review of randomized controlled trials published between 1996 and 2011 examining the relation between algal oil supplementation and cardiovascular disease risk factors, performing a meta-analysis of the association between algal oil DHA supplementation and changes in triglyceride (TG), LDL-C, and HDL-C concentrations. They identified 11 RCTs with 485 healthy participants; the median dose of algal DHA was 1.68 g/d. The pooled estimate for the change in TG concentration was −0.20 mmol/L (95% CI: −0.27 to −0.14), 0.23 mmol/L (95% CI: 0.16–0.30) for LDL-C, and 0.07 mmol/L (95% CI: 0.05–0.10) for HDL-C, suggesting that DHA supplementation from algal oil may reduce serum TG and increase HDL-C and LDL-C in persons without coronary heart disease.
Regarding broader cardiovascular event outcomes, although results from individual RCTs have been inconsistent — with REDUCE-IT and RESPECT-EPA demonstrating significant benefit, and STRENGTH, VITAL, OMEMI, and OMEGA-REMODEL yielding modest or neutral results — meta-analyses aggregating data from multiple RCTs generally support a significant reduction in major cardiovascular events. Notably, EPA monotherapy appears more effective than combined EPA + DHA formulations. Evidence for primary prevention of CVD through RCTs is relatively weak. In high-risk patients, especially in the secondary prevention setting (e.g., post-MI), a number of large RCTs support the use of EPA + DHA (or EPA alone) as confirmed through a recent meta-analysis.
In some subjects, blood pressure and heart rate were significantly reduced. Algal-DHA was safe and well tolerated. Unlike fish oil, algal-DHA seldom caused gastrointestinal complaints such as fishy taste and eructation — attributes of importance for patient compliance in high-dose therapy.
Evidence strength: Mixed. Some support for short-term neurological benefits, especially in specific subpopulations; inconsistent effects on standardized global developmental scores.
As an important source of DHA, algal oil has been used in research designs to define the nutrient-specific benefits to infant development and to cardiovascular and cognitive health in adults. DHA rapidly accumulates in the brain and retina during gestation and early infancy and is essential for infant growth and maturation.
Algal oils have been used in the infant formula industry for many years, providing DHA at a concentration to match that present in human breast milk, and evidencing their safety. Algal oils have been shown to increase EPA and DHA status in blood cells in adults just like fish oil does.
One large RCT from India enrolled 957 women and tested 400 mg/d of algal DHA from ≤20 weeks gestation through 6 months postpartum. Researchers conducted a double-blind, randomized, placebo-controlled trial to test the effectiveness of supplementing pregnant Indian women from ≤20 weeks through 6 months postpartum with 400 mg/d algal DHA compared to placebo on neurodevelopment of their offspring at 12 months. At 12 months, the mean development quotient (DQ) scores in the DHA and placebo groups were not statistically significant (96.6 ± 12.2 vs. 97.1 ± 13.0, p = 0.60). Supplementing mothers with 400 mg/d DHA through pregnancy and lactation did not impact offspring neurodevelopment at 12 months of age in this setting.
A 2015 RCT using algal DHA supplementation at 200 mg/d in breastfeeding mothers likewise found no significant effect on visual function at 5 years of age. Breastfeeding women received identical capsules containing either DHA algal oil (200 mg/d of DHA) or a vegetable oil (no DHA) from delivery until 4 months postpartum. The results showed that at 5 years, there were no differences in visual function, transient visual evoked potential, or sweep visual evoked potential testing between children whose mothers received DHA versus placebo.
A 2024 systematic review and meta-analysis addressed the broader evidence base: DHA plays a crucial role in the growth and functional development of the infant brain. However, the impact of additional DHA supplementation on neurodevelopment in infants remains controversial in randomized controlled trials. Supplementation for infants with DHA is effective for neurodevelopment, but this only shows a significant advantage in psychomotor development index (PDI), and the results differ with different conversion methods. Therefore, more high-quality evidence is needed to confirm the benefit of DHA supplementation in infants and young children. For pregnant women, results were inconsistent, although DHA intake during pregnancy is important to ensure that the fetus obtains an adequate level.
With respect to infant formula specifically, an FDA GRAS review concluded that there are no adverse effects associated with 1% DHA in infant formulas, with some studies suggesting a benefit to stature and body composition. Preterm infants fed 1.0% DHA and weighing ≥1,250 g at birth were up to 1.7 cm longer at 18 months corrected age compared to infants fed 0.35% DHA. In those weighing <1,250 g at birth, head circumference was greater in response to 1% DHA at expected delivery date.
Evidence strength: Moderate, particularly for women with low baseline DHA status. Effects appear subgroup-specific.
In people who get less DHA from their diet, taking DHA-enriched algal oil by mouth during pregnancy seems to lower the risk of having a baby very early.
A key U.S. trial (ADORE) specifically used an algal oil supplement. The ADORE trial was a comparative effectiveness trial conducted in the United States, wherein an algal supplement of 1,000 mg/d DHA was compared with 200 mg/d DHA in 1,100 pregnancies. The higher dose reduced early preterm birth (PTB) (Bayesian posterior probability = 0.81); however, a secondary analysis showed that the reduction was for the 43% of women who entered the trial with low baseline DHA status (n=468/1,100).
Algal oils providing DHA have been shown to raise DHA status in pregnant women and such supplements have been used in many of the trials investigating omega-3 LC-PUFAs and risk of PTB.
Evidence strength: Weak to mixed. Current evidence does not support broad cognitive enhancement in most children or adults with adequate baseline DHA status.
Taking DHA-enriched algal oil by mouth does not seem to improve cognitive function or reading ability in most children. Experimental animal studies and observational human studies have shown positive associations between intakes during pregnancy of EPA and DHA and a range of measures of offspring neurodevelopment. The published RCTs examining the effects of prenatal supplementation on child development have used fish oil supplements containing both EPA and DHA and have reported inconsistent effects on infant cognitive development. One RCT added to the growing body of evidence suggesting that prenatal DHA supplementation does not have a significant overall positive effect on global measures of infant development.
Evidence strength: Preliminary. Most available data are from animal and in vitro studies; limited human clinical data.
Previous studies have shown that antibiotic-induced disturbances of the intestinal barrier and intestinal microbiota can be modulated by supplementation with n-3 PUFAs such as algal oil and fish oil. Supplementation of algal oil upregulated the concentration of tight junction protein ZO-1; tight junction protein integrity strengthens the intestinal barrier, thereby limiting the entry of antigens and preventing adverse immune reactions. These findings are primarily from animal models, and human translation requires further study.
Evidence strength: Weak to moderate. Epidemiological associations exist, but RCT evidence is limited.
DHA levels are especially high in retina (eye) cells. The omega-3s in algal oil may help slow how quickly tears evaporate, easing symptoms of dry eyes. EPA and DHA can also help ease eye irritation in those who wear contacts or work in front of computers. The fatty acids may even help to lower the odds of age-related macular degeneration. However, these claims are based predominantly on epidemiological data and observational studies rather than high-quality RCTs specifically using algal oil.
Evidence strength: Weak. Current evidence does not support efficacy for these conditions.
Taking DHA-enriched algal oil by mouth does not seem to improve symptoms of cystic fibrosis. Taking algal oil by mouth does not seem to reduce the risk of fractures in older adults. Taking algal oil by mouth does not seem to improve muscle strength in older adults.
A key question for algal oil consumers is whether its DHA and EPA are as bioavailable as those from fish oil. Algal oils have been used in the infant formula industry for many years, providing DHA at a concentration to match that present in human breast milk, and evidencing their safety. Algal oils have been shown to increase EPA and DHA status in blood cells in adults just like fish oil does.
Algal oil has certain advantages over fish oil for the production of omega-3 fatty acids. Consistency of composition, sensory properties such as aroma, taste, texture, and appearance, ease of production, lack of contaminants, and low cholesterol are key features of omega-3 fatty acid production using algal oil.
Microalgal oils may serve purposes across pharmaceutical, nutraceutical, cosmetic and food industries. The PUFAs obtained from oleaginous microalgae show benefits over other PUFA sources such as fish oils, being odorless and non-dependent on fish stocks.
Algal-derived EPA and DHA are a sustainable alternative to consuming fish or using fish as the source of oil for supplements, and help protect the planet by avoiding overfishing to meet human needs. Algal oils are also suitable for vegetarian and vegan consumers as supplemental sources of omega-3 LC-PUFAs.
Algal oil is available primarily in softgel capsule form and as a liquid oil. It is also incorporated into food products such as infant formula, fortified dairy, juices, and nutrition bars. The following dosages reflect those reported in clinical studies or referenced in authoritative sources:
Algal oil rich in DHA is likely safe when taken by mouth; it has been used safely for up to 4 years. Algal oil rich in EPA is possibly safe, having been used safely for up to 3 months. Most side effects are mild and might include fishy burps and stomach symptoms.
Commonly reported side effects of omega-3 supplements are usually mild. These include unpleasant taste, bad breath, heartburn, nausea, gastrointestinal discomfort, diarrhea, headache, and odoriferous sweat.
Taking high doses of algal oil providing more than 3 grams of DHA and EPA daily is possibly unsafe. High doses might slow blood clotting and increase the chance of bleeding. Some algal oil contains the omega-3 fatty acids DHA and EPA. DHA alone does not seem to affect blood clotting. But taking algal oil in doses providing more than 3 grams daily of EPA and DHA might increase the risk of bleeding.
Increased incidence of hemorrhagic stroke and excessive bleeding times have been reported. High intakes of omega-3 fatty acids may be necessary to obtain clinically relevant blood pressure reductions, and at high dose levels there is an increased risk of bleeding.
Omega-3 dietary supplements, such as fish oil and by extension algal oil, have the potential to interact with medications. This is especially important for individuals on polypharmacy with multiple comorbidities, like those with hepatic and pancreatic impairment, those taking anticoagulants, and individuals with a possible fish sensitivity. The anticoagulant interaction is the most clinically significant, given that high-dose omega-3 supplementation may potentiate the effect of anticoagulants such as warfarin or antiplatelet agents.
Algal oil that is rich in DHA is likely safe when taken by mouth during pregnancy or breastfeeding. Algal oil is included in some prenatal vitamins and infant formulas as a source of DHA. When taken while pregnant or breastfeeding, DHA levels in the breast milk increase. Most experts recommend consuming 300 mg of DHA daily while pregnant and breastfeeding.
Infant formula is subject to additional statutory and regulatory requirements provided in 21 CFR 106 and 107 to ensure the nutritional quality and safety of what is considered the "sole source of nutrition by a vulnerable population during a critical period of growth and development." FDA scientists reviewing early GRAS filings for Martek's algal DHA oil noted that some studies had reported adverse events and other morbidities including diarrhea, flatulence, jaundice, and apnea in infants fed long-chain polyunsaturated fatty acids, and requested post-market surveillance. However, subsequent reviews concluded there are no adverse effects associated with 1% DHA in infant formulas, with some studies suggesting a benefit to stature and body composition.
Omega-3 fatty acids are vital for human health, yet traditional sources such as fish oils face challenges including overfishing, environmental concerns, and contaminants. Because algal oil is produced in controlled fermentation tanks, it avoids the accumulation of heavy metals (such as mercury) and other environmental pollutants that can occur in marine fish. Certain types of seafood — especially larger predatory fish such as shark, swordfish, king mackerel, and tilefish — tend to accumulate higher levels of mercury. Mercury is a neurotoxin that can be harmful, particularly to the developing nervous systems of fetuses and young children. Algal oil, derived from controlled fermentation rather than wild-caught fish, does not carry this contamination risk.
Condiciones de salud que aceite de algas puede ayudar a apoyar.
DHA from algal oil supports antioxidant defense by enhancing endogenous antioxidant enzyme activity and reducing lipid peroxidation. Animal studies using algal DHA showed increased superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity alongside reduced oxidative biomarkers. A 2024 study confirmed DHA can alleviate retinal damage from oxidative stress.
DHA from algal oil is linked to reduced anxiety through modulation of neurotransmitter pathways. A 12-month RCT found that DHA+EPA supplementation reduced anxiety scores specifically in APOE ε4 carriers with mild cognitive impairment. Animal and epidemiological data also associate low DHA status with heightened susceptibility to stress and anxiety.
Algal oil DHA improves arterial compliance and reduces stiffness, contributing to vascular protection. Clinical data show that DHA and EPA enhance endothelial function and increase systemic arterial compliance in humans. These effects are mediated through vasodilatory and anti-inflammatory mechanisms.
Omega-3 fatty acids including DHA from algal oil reduce joint inflammation and pain through anti-inflammatory mechanisms including suppression of pro-inflammatory cytokines. Clinical data from fish oil RCTs (directly applicable given algal oil bioequivalence) show reductions in joint stiffness and pain in inflammatory arthritis. Expert pharmacy guides recommend algal oil omega-3s as complementary to conventional arthritis treatment.
Children with ADHD have lower blood levels of long-chain PUFAs including DHA compared to children without ADHD, and PUFA supplementation has shown improvements in ADHD-related symptoms. Two meta-analyses found positive but small effect sizes for LC PUFAs including DHA on behavioral symptoms in children and adolescents with ADHD. The DOLAB trial used algal oil DHA (600 mg/day) directly in underperforming school children.
DHA and EPA from algal oil inhibit platelet activation and aggregation, reducing thrombotic risk. Clinical and in vitro studies confirm that omega-3 PUFAs inhibit platelet activation, lipoprotein oxidation, and pro-thrombotic eicosanoid production. At high doses (>3 g/day), algal oil can affect blood clotting, which is why the FDA sets an upper limit of 5 g combined DHA+EPA/day from supplements.
DHA from algal oil has been shown to lower ambulatory blood pressure and heart rate in clinical studies. A dose-response meta-analysis incorporating algal oil trials found that omega-3 PUFAs significantly lower both systolic and diastolic blood pressure. DHA activates large-conductance K+ channels in vascular smooth muscle, causing vasodilation as a proposed mechanism.
Algal oil DHA supplementation during breastfeeding increases DHA concentrations in breast milk, ensuring adequate supply of this essential fatty acid to nursing infants. Multiple RCTs confirm this transfer, and expert guidelines recommend 200–300 mg DHA/day for lactating mothers. Algal oil is recognized as a safe, fish-free source for this purpose.
Algal oil DHA specifically reduces serum triglycerides and modestly raises HDL-cholesterol, while also increasing LDL-cholesterol with a shift toward larger, less atherogenic LDL particles. A dedicated meta-analysis of 11 algal oil DHA RCTs (n=485) quantified these effects precisely. At 1–2 g/day, algal DHA lowers triglycerides by up to 26%.
DHA from algal oil exerts anti-inflammatory effects by competing with arachidonic acid pathways and producing specialized pro-resolving mediators (resolvins and protectins). These mechanisms reduce circulating inflammatory cytokines including TNF-α, IL-1β, and IL-6. Higher omega-3 intake is associated with lower C-reactive protein levels in clinical populations.
Algal oil DHA has been directly tested in cognitive aging RCTs. The MIDAS trial (900 mg algal DHA/day, n=485, 24 weeks) demonstrated significantly fewer paired associative learning errors in older adults with mild memory complaints. DHA levels are inversely associated with dementia risk in observational data, and algal DHA improves cognitive biomarkers in aging animal models.
DHA from algal oil may reduce depressive symptoms by modulating serotonin and dopamine neurotransmitter systems. Consumption of larger amounts of DHA is associated with reduced risk of depression and mood disorders in epidemiological data. An RCT in APOE ε4 carriers found a significant effect of DHA+EPA on depression scores.
Omega-3s in algal oil, particularly DHA and EPA, may ease dry eye symptoms by slowing tear evaporation and reducing ocular surface inflammation. Clinical reviews support omega-3 supplementation for dry eye relief, with effects attributed to DHA's anti-inflammatory properties in the lacrimal gland and ocular surface. Benefits have been noted for contact lens wearers and screen users.
DHA is a major structural fatty acid in the retina, accounting for approximately 20% of its weight, and is essential for normal visual function across the lifespan. Algal oil DHA supplementation in infant formula has been shown to improve visual acuity in formula-fed infants. DHA plays ongoing roles in retinal membrane function and protection from oxidative stress.
Algal oil DHA has been investigated for anti-aging effects through reduction of oxidative stress, neuroinflammation, and cognitive decline markers. In animal aging models, algal DHA supplementation significantly improved cognitive performance, enhanced antioxidant enzyme activity, and reduced amyloid-beta accumulation. DHA also shows associations with reduced risk of age-related diseases including dementia.
DHA from algal oil is critical for fetal and infant brain and eye development, with DHA accumulating in brain and retinal tissues during late fetal and early neonatal life. Maternal algal oil supplementation transfers DHA to the fetus and breast milk. Algal oil is used in infant formula specifically to support neurological and visual development.
Algal oil DHA reduces cardiovascular risk through triglyceride lowering, improvement of lipoprotein particle size, modest blood pressure reduction, and anti-inflammatory and antiplatelet effects. A meta-analysis of 11 RCTs (n=485) demonstrated that algal DHA significantly lowers serum triglycerides and raises HDL-cholesterol. At 1–2 g/day, algal DHA reduces triglycerides by up to 26%.
DHA accounts for approximately 20% of retinal weight and is the dominant structural fatty acid in the macula. Population studies show an inverse association between omega-3 intake and AMD risk. Cohort studies and twin studies show that high n-3 PUFA and seafood intake may protect against both early and late AMD; however, RCT results with DHA supplementation are mixed.
Algal oil DHA has been directly tested for memory improvement in clinical trials. The landmark MIDAS trial (n=485, 900 mg algal DHA/day, 24 weeks) found significantly fewer paired associative learning errors versus placebo in healthy older adults with mild memory complaints. A meta-analysis confirmed that DHA+EPA doses above 580 mg/day improve episodic memory in adults with mild memory complaints.
Omega-3 PUFAs including DHA from algal oil significantly improve key components of metabolic syndrome—including elevated triglycerides, high blood pressure, and dyslipidemia. A systematic review and meta-analysis of RCTs in metabolic syndrome patients found n-3 PUFAs significantly decreased serum triglycerides, systolic blood pressure, and diastolic blood pressure.
DHA is an essential structural component of neuronal membranes throughout the nervous system and is critical for normal development and maintenance of neuronal function. Deficiency of DHA in the nervous system is associated with multiple neurological and psychiatric conditions. Algal oil provides a direct source of DHA that supports neuronal membrane integrity and neurotransmitter signaling.
DHA stores are depleted during pregnancy as the fetus draws heavily on maternal supplies, making postpartum DHA replenishment important. Algal oil provides a safe, fish-free source of DHA for postpartum women. DHA supplementation during this period supports maternal cognitive function, mood, and continued supply of DHA to infants via breast milk.
Algal oil is the primary plant-based (vegan-friendly) source of long-chain omega-3 DHA for prenatal supplementation. Clinical studies confirm algal oil DHA supplementation during pregnancy raises maternal and fetal DHA status equivalently to fish oil. It is recommended by ACOG and dietary guidelines as the sustainable, contaminant-free DHA source for vegetarian and vegan pregnant women and is used in many commercial prenatal vitamins.
DHA and EPA from omega-3 sources including algal oil reduce inflammation and cytokine levels relevant to rheumatoid arthritis pathophysiology. Multiple clinical studies show reductions in plasma IL-1β, TNF-α, and IL-6 with fish oil supplementation—directly applicable to algal oil given confirmed bioequivalence. Omega-3s provide complementary anti-inflammatory benefit in RA management.
Algal oil is a vegetarian/vegan source of DHA (and sometimes EPA) derived from marine microalgae. It provides the same long-chain omega-3s as fish oil at equivalent doses and has comparable triglyceride-lowering bioavailability, making it an evidence-based alternative for individuals who avoid fish products.
Sistemas corporales que aceite de algas puede ayudar a apoyar.
Volver